Lucid Diagnostics Common Stock Over Time

LUCD Stock  USD 0.79  0.02  2.60%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Lucid Diagnostics Performance and Lucid Diagnostics Correlation.
For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.
  
As of December 14, 2024, Common Stock is expected to decline to about 28.6 K. In addition to that, Common Stock Shares Outstanding is expected to decline to about 41.1 M.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.12)
Revenue Per Share
0.09
Quarterly Revenue Growth
0.497
Return On Assets
(1.01)
Return On Equity
(10.08)
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Common Stock Analysis

Compare Lucid Diagnostics and related stocks such as Inari Medical, Beyond Air, and PAVmed Series Z Common Stock Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
NARI6.3 K6.3 K6.3 K6.3 K6.3 K6.3 K6.3 K6.3 K6.3 K6.7 K49 K50 K54 K58 K41.1 K
XAIR29 K29 K29 K29 KKKK8408711.6 KKKKK3.5 K
PAVMZ10.9 K10.9 K10.9 K10.9 K10.9 K12.2 K13.3 K14.6 K27.1 K40.5 K64 K86 K95 KK8.6 K
CLPT164.1 K164.1 K484.2 K585.4 K748.4 K913.8 K36.2 K106.9 K110.2 K152.4 K170 K237 K246 K247 K258.6 K
LIVN200 K306.4 K312.9 K318.2 K320.5 K75.4 M74.6 M74.8 M76.1 M76.3 M76.3 M82.3 M82.4 M82.5 M86.7 M
ELMD58.8 K81.1 K81.1 K81.1 K81.3 K81.9 K82.3 K82.9 K84.1 K85.7 K85 K85 K86 K87 K87.1 K
KIDS1000100010001000100010001000KKKKKK6.9 K3.9 K
SRDX400 K733 K695 K680 K647 K660 K655 K670 K675 K684 K695 K701 K708 K716 K612.3 K
NPCE1000100010001000100010001000100010001000100024 K25 K28 K17.4 K
FNA84 K84 K84 K84 K84 K84 K84 K84 K84 K84 K93 K763 K776 K827 K559.5 K
CVRXKKKKKKKKKKK204 K207 K209 K138.4 K
LUNG16 K16 K16 K16 K19.7 K21.5 KK3.9 K17 K19 K36 K37 K38 K39 K25 K
IRMD7007007007001.1 K1.1 K1.1 K1.1 K1.1 K1.2 K1.2 K1.3 K1.3 K1.3 K1.2 K
OFIX1.3 M1.8 M1.9 M1.8 M1.9 M1.9 M1.8 M1.8 M1.9 M1.9 M1.9 MMM3.7 MM
ITGR12 K23 K24 K24 K25 K31 K31 K32 K33 K33 K33 K33 K33 K38 K28.1 K

Lucid Diagnostics and related stocks such as Inari Medical, Beyond Air, and PAVmed Series Z Common Stock description

My Equities

My Current Equities and Potential Positions

Lucid Diagnostics
LUCD
Specialization
Health Care, Health Care Equipment & Services
LocationNew York; U.S.A
ExchangeNASDAQ Exchange
USD 0.79
When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:
Check out Lucid Diagnostics Performance and Lucid Diagnostics Correlation.
For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Lucid Diagnostics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Lucid Diagnostics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Lucid Diagnostics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...